The U.S. Food and Drug Administration (FDA) has accepted a new drug application for iberdomide combined with Darzalex ...

Relapsed and refractory multiple myeloma can be difficult to manage, especially as patients progress through multiple lines of therapy and treatment options may become more limited. 1 Since the ...

Study expected to enroll 24 patients with the option to enroll an additional 45 patients at the recommended Phase 2 doseProtocol calls for three ...

Bristol Myers Squibb said the U.S. Food and Drug Administration has granted priority review to its application seeking approval of its iberdomide drug candidate in certain patients with the blood ...

Chemotherapy is a treatment that uses strong medicines to kill cancer cells or slow their growth. It is a type of systemic therapy, which means it travels through the bloodstream to reach and attack ...

Ameet Patel, MD, explains how multiple myeloma treatment settings depend on safety, logistics, and patient needs.

Genetic testing should be offered to myeloma patients to identify high-risk cases earlier and enable more targeted and effective treatment, according to experts. A study by The Institute of Cancer ...

Kyprolis is a type of medicine called a proteasome inhibitor. The proteasome is like the cell's "trash disposal" system. Proteasome inhibitors such as Kyprolis bind to and block the activity of the ...

Dr. Lisa Hicks and Dr. Joseph Mikhael discuss the updated guideline from ASCO and Ontario Health (Cancer Care Ontario) on the treatment of multiple myeloma. They cover recommendations for therapeutic ...

Radiation therapy is a treatment that uses high doses of radiation to damage cancer cells, either killing them or slowing their growth. Unlike the low-dose radiation used in X-rays to see inside the ...

Renowned Hindi and Marathi actress Pravina Deshpande passed away at 60 after battling multiple myeloma since 2019. Known for Ghar Ek Mandir, Kumkum, and films like Ready, she faced skin eruptions, ...

Minimal residual disease (MRD) refers to the small number of myeloma cells that may remain after treatment and are not detectable using conventional response criteria. In multiple myeloma, MRD ...